Fasting-Mimicking Diet Modulates Microbiota and Promotes Intestinal Regeneration to Reduce Inflammatory Bowel Disease Pathology
A study in a mouse model of colitis. It did not test inflammatory bowel disease in people.
Cell Rep, 2019. Rangan P, et al.
Funding and competing interests (as published with the paper): DECLARATION OF INTERESTS V.D.L. has equity interest in L-Nutra, which develops and sells medical food for the prevention and treatment of diseases. V.D.L. has committed all his equity in the company to charitable organizations. V.D.L., P.R., and I.Y.C. have filed a patent related to this study at the University of Southern California (USC).
- Study type
- Animal study (mice), with human data cited from another trial
- Journal
- Cell Rep
- Published
- 2019
- Authors
- Rangan P, et al.
- DOI
- 10.1016/j.celrep.2019.02.019
- PubMed ID
- 30840892
Summary
Researchers tested 4-day Fasting Mimicking Diet (FMD) cycles in mice with chemically induced colitis (an inflammatory bowel disease model), and also reported systemic inflammation markers from an existing human clinical trial of FMD cycles.
In mice, the authors reported that FMD cycles reduced intestinal inflammation, increased intestinal stem cell numbers, encouraged protective gut bacteria, and reversed colitis-related damage, with gut bacteria transplanted from FMD-treated mice reproducing some of these effects in other mice. In the human trial data cited, the authors reported that three consecutive monthly FMD cycles reduced markers of systemic inflammation.
The intestinal-regeneration and colitis-reversal findings are from a mouse model, not people; the human data point is limited to general inflammation markers, not an inflammatory-bowel-disease outcome in human patients. This study does not show that an FMD treats or reduces inflammatory bowel disease in people.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
